Zydus Cadila receives tentative approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules

Ahmedabad, 30 March 2013

Zydus Cadila has received tentative approval from the USFDA for Amlodipine Besylate and Benazepril Hydrochloride Capsules, in the strengths of 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg. It falls in the anti-hypertensive segment.

The estimated sales in 2012 as per IMS for Amlodipine Besylate and Benazepril Hydrochloride Capsules, was USD 384.8 million.

The group now has 78 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.
